Literature DB >> 2886441

Monoclonal integration of HTLV-I proviral DNA in patients with strongyloidiasis.

K Nakada, K Yamaguchi, S Furugen, T Nakasone, K Nakasone, Y Oshiro, M Kohakura, Y Hinuma, M Seiki, M Yoshida.   

Abstract

The relationship between strongyloidiasis and HTLV-I was investigated in Okinawa, an area where both conditions are endemic. Thirty-six patients with strongyloidiasis were seropositive for HTLV-I and suffered from several related clinical complications. Fourteen of these patients (39%) were shown to have monoclonal integration of HTLV-I proviral DNA in their blood lymphocytes, a condition designated as "smouldering" adult T-cell leukaemia (ATL). Monoclonal integration of proviral DNA correlated with an increased CD4/CD8 ratio and the presence of abnormal lymphocytes in the peripheral blood, and with a trend for greater severity of the parasitic infection. Although the immunodeficiency caused by HTLV-I could predispose to hyperinfestation by Strongyloides, it is also possible that both the parasitic and the retroviral infestations are important co-factors leading to the development of ATL.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886441     DOI: 10.1002/ijc.2910400203

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  28 in total

Review 1.  Dysregulation of strongyloidiasis: a new hypothesis.

Authors:  R M Genta
Journal:  Clin Microbiol Rev       Date:  1992-10       Impact factor: 26.132

Review 2.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

3.  Induction of multiple independent T-cell lymphomas in rats inoculated with MOloney murine leukemia virus.

Authors:  A Bellacosa; P A Lazo; S E Bear; S Shinton; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

4.  Characterization of patients with aggressive adult T-cell leukemia-lymphoma in Okinawa, Japan: a retrospective analysis of a large cohort.

Authors:  Yukiko Nishi; Takuya Fukushima; Shogo Nomura; Takeaki Tomoyose; Sawako Nakachi; Kazuho Morichika; Iori Tedokon; Keita Tamaki; Natsuki Shimabukuro; Naoya Taira; Takashi Miyagi; Kaori Karimata; Masayo Ohama; Atsushi Yamanoha; Kazumitsu Tamaki; Masaki Hayashi; Hitoshi Arakaki; Jun-Nosuke Uchihara; Kazuiku Ohshiro; Yoshitaka Asakura; Megumi Kuba-Miyara; Kennosuke Karube; Hiroaki Masuzaki
Journal:  Int J Hematol       Date:  2016-06-21       Impact factor: 2.490

5.  Two-step nature of human T-cell leukemia virus type 1 replication in experimentally infected squirrel monkeys (Saimiri sciureus).

Authors:  F Mortreux; M Kazanji; A S Gabet; B de Thoisy; E Wattel
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 6.  Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy.

Authors:  M Matsuoka; K-T Jeang
Journal:  Oncogene       Date:  2010-11-29       Impact factor: 9.867

7.  Strongyloidiasis associated with human T-cell lymphotropic virus type I infection in a nonendemic area.

Authors:  A C Dixon; E T Yanagihara; D W Kwock; J M Nakamura
Journal:  West J Med       Date:  1989-10

Review 8.  Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management.

Authors:  Sue Lim; Kevin Katz; Sigmund Krajden; Milan Fuksa; Jay S Keystone; Kevin C Kain
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

9.  High human T cell leukemia virus type-1(HTLV-1) provirus load in patients with HTLV-1 carriers complicated with HTLV-1-unrelated disorders.

Authors:  Daisuke Sasaki; Yuko Doi; Hiroo Hasegawa; Katsunori Yanagihara; Kunihiro Tsukasaki; Masako Iwanaga; Yasuaki Yamada; Toshiki Watanabe; Shimeru Kamihira
Journal:  Virol J       Date:  2010-04-28       Impact factor: 4.099

10.  Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1.

Authors:  M Satoh; S Kiyuna; Y Shiroma; H Toma; A Kokaze; Y Sato
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.